Tmunity Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tmunity Therapeutics Inc.
Private Company Edition: The amount of venture capital investment in biopharma companies has shrunk from quarter to quarter, but the average deal size remained high until the third quarter. Larger rounds from Treeline, Odyssey and Neumora offset a plethora of smaller VC financings early in Q4.
Plus deals involving Aculys/Neurelis, Xtalpi/Excelra, Abbisko/Lilly, Daiichi Sankyo/Cosette, Mitsubishi Tanabe/ADC Therapeutics and PersonGen/Transgene.
Developing CAR-Ts against solid tumors that are both safe and effective is proving a huge technical challenge, but San Diego biotech Poseida believes it has made important progress.
A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.
- Gene Therapy, Cell Therapy